Go Pro
NASDAQ:GRCE

Grace Therapeutics Q1 2027 Earnings Report

Grace Therapeutics logo
$2.16 +0.09 (+4.35%)
Closing price 04:00 PM Eastern
Extended Trading
$2.19 +0.03 (+1.39%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics EPS Results

Actual EPS
-$0.91
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.78
One Year Ago EPS
-$0.21

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.40 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q1 2027
Time
Before Market Opens
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
7:00AM ET

Grace Therapeutics Earnings Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Grace Therapeutics (GRCE) Expected to Release Earnings on Tuesday
Grace Therapeutics, Stock Price History
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways.

Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.

View Grace Therapeutics Profile